In the early 21st century, it was demonstrated that plasma (physical plasma and not blood plasma) can be used for biomedical applications. Non equilibrium plasma has the ability to generate large population densities of reactive species, while keeping the overall gas temperature near room temperature (below 40°C), allowing the plasma to be in direct contact with living tissues with no risk of burning (cf the picture below). This singular feature led to the development of a new area, called Plasma Medicine. Research is now performed on many different topics including work on cancer treatment, wound healing, blood coagulation, dentistry, cosmetology, sterilization and decontamination, among others. The successes of plasmas have come so far from their versatility and their capacity to generate large amounts of reactive species combined with electric field, photons (IR, visible and UV) and charged particles. All these components can act on tissues and their combination induces synergetic effects 1.
A great number of the species produced by plasma are reactive oxygen and nitrogen species (RONS), such as atomic oxygen, ozone (O3), nitric oxide (NO) and hydroxide (OH), produced by the interaction of the plasma with air. These RONS are known to have various beneficial effects such as antibacterial and vasodilator properties. But surprisingly, the role of CO has so far been neglected in biological plasma treatment 2, while this molecule has many beneficial effects for human health and has a broad spectrum of biological activities such as anti-inflammatory, vasodilator, anti- apoptotic, and anti-proliferative effects, and can be easily produced by plasma by the dissociation of CO2 3.
The work will be dedicated to the study of the effects of CO produced by plasma on wound healing. It is summarized into three tasks:
1 E. Carbone and C. Douat, Plasma Med., vol. 8, no. 1, pp. 93–120, 2018.
2 C. Douat, P. Escot Bocanegra, S. Dozias, É. Robert, and R. Motterlini, Plasma Process. Polym., vol. 18, no. 9, p. 2100069, Sep. 2021.
3 R. Motterlini and L. E. Otterbein, Nat. Rev. Drug Discov., vol. 9, no. 9, pp. 728–743, Sep. 2010.Context and work environment
This work will be a collaboration between the GREMI laboratory in Orleans and the INSERM laboratory in Creteil (University Paris-East). GREMI is a laboratory specialized on the study of plasma reactors for biomedical applications and is composed of plasma physicists and chemists. The team number 12 in Creteil is specialized in CO biology and is composed of biologists.Additional comments Information
Workplace: the first 6 months: GREMI (Orleans, France) and the last 18 months: INSERM (Creteil, France)
Contract period: 24 month
Starting date: from February 2023 (but it is flexible)Offer Requirements
Biological sciences: PhD or equivalentSkills/Qualifications Skills